对老年冠心病患者实施不同剂量阿托伐他汀治疗的可行性分析

目的 分析对老年冠心病患者实施不同剂量阿托伐他汀治疗的可行性。方法 随机将该院收治的80例患者分为对照组和观察组,临床对A组患者主要采用40 mg阿托伐他汀治疗,对B组患者采用20 mg阿托伐他汀治疗,并观察两组患者治疗效果。结果 治疗后TG、TC以及LDL-cC水平均与一定程度的下降,两组患者治疗前后相比差异有统计学意义（P〈0.05）;治疗后两组患者相比A组HDL-C（1.24±0.39）升高水平明显高于B组HDL-C（1.12±0.41）,且A主要TG（1.10±0.43）、TC（3.30±0.65）以及LDL-cC（1.06±0.49）下降水平明显低于B组TG（1.38±0.47）,TC（4.42±0.64）以及LDL-cC（1.65±0.42）,两组相比差异有统计学意义（P〈0.05）。两组不良反应发生率比较,差异无统计学意义（P〉0.05）。结论 大剂量阿托伐他汀应用于老年冠心病的治疗中疗效优于小剂量阿托伐他汀。

Feasibility Analysis of Different Doses of Atorvastatin Treatment for Elderly Patients with Coronary Heart Disease

Objective To analyze the feasibility of the implementation of different doses of atorvastatin in the treatment of elderly patients with coronary heart disease. Methods A total of 80 cases admitted in our hospital were randomly divided into the control group and the observation group. The patients in group A were mainly given 40rag atorvastatin for clinical treatment, and patients in group B were given 20mg atorvastatin for treatment. And the treatment effect was observed in two groups. Results After treatment, TG, TC and LDL-cC levels of the two groups were associated with a certain degree of decline, the differences in TG, TC and LDL-cC levels of the two groups before and after treatment were statistically significant （both P〈0.05）; after treatment, the elevated HDL-C level of group A was （1.24±0.39）, significantly higher than that （1.12±0.41） of group B, the decreased level of TG, TC and LDL-cC of group A was（1.10±0.43）,（3.30±0.65） and （1.06±0.49）, respectively, significantly lower than （1.38±0.47）, （4.42±0.64） and （1.65±0.42） of group B, respectively, the differences were statistically significant（all P〈0.05）. The difference in the incidence of adverse reactions between the two groups was not statistically significant, P〉0.05. Conclusion The therapeutic effect of high dose atorvastatin for elderly coronary heart disease is better than that of low dose atorvastatin.